ArticleJournal of medical cases2026
Aggressive Primary Sacral Non-Hodgkin Lymphoma Associated With Systemic Lupus Erythematosus.
Article in Journal of medical cases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this case report, we discuss a 36-year-old female patient diagnosed with a rare and aggressive sacral non-Hodgkin lymphoma. The patient presented with a rapidly progressive low back pain radiating to both lower limbs and, following a neurosurgical resection, was diagnosed with sacral non-Hodgkin lymphoma. Sacral involvement is rare among bone pathologies, accounting for only 1-7% of all spinal tumors. The association of this neoplasm with systemic lupus erythematosus at this anatomical site is uncommon and was correlated with an aggressive clinical course in our patient. Magnetic resonance imaging revealed lytic and infiltrative lesions involving the sacrum and L4 on T1- and T2-weighted sequences. Histopathological and immunohistochemical analyses confirmed a diagnosis of diffuse large B-cell lymphoma, expressing CD20, Bcl-6, Bcl-2, CD10, PAX-5, MUM-1, and c-MYC, with a high proliferative index (Ki-67: 90%), and negative for CD3, CK AE1/AE3, CD30, and TdT. During disease progression, the patient developed multiple metastases involving the brain, breast, lung, and submandibular lymph node. Despite treatment with combined chemotherapy and radiotherapy, the aggressive nature of the disease resulted in a poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.